BRAF检验市场:各市场区隔规模，占有率，法律规章，偿付，2033年为止的预测

使用活检组织进行 BRAF 测试以检测 BRAF V600 突变蛋白或 BRAF 基因突变，结果有望指导黑色素瘤的治疗。 BRAF 基因属于一组称为癌基因的基因。当癌症基因突变时，它们会导致正常细胞癌变。

BRAF 基因为製造将特定讯号从细胞外传递到细胞核的蛋白质提供了指导。该蛋白是 RAF/MAPK 讯号通路的一部分，该通路控制多种重要的细胞功能。特别是，RAF/MAPK 路径指导细胞发育和分裂（增殖）、细胞发育成特定功能（分化）、细胞运动（迁移）和细胞破裂（凋亡）的步骤。

本报告提供全球BRAF检验市场相关资料详细考察，提供市场上竞争情形，SWOT分析，到2033年为止的市场预测，地区，各国的趋势等资讯。

目录

已上市的BRAF检验和不断变化的竞争格局

• 主要的产业趋势洞察
• BRAF检验的各市场区隔整体市场收益和2015年～2033年的市场展望
• 件数，平均销售价格，市场价值相关详细资料

世界，地区，各国洞察

• BRAF检验市场SWOT分析
• BRAF检验市场相关竞争动态的洞察和趋势
• 各国医疗制度概要
• 各国偿付政策
• 各国医疗技术相关法规状况

BRAF Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.

BRAF tests are carried out to detect either the BRAF V600 mutant protein or mutations in the BRAF gene, using biopsied tissue, the outcome of which may guide therapies to treat melanoma cancer. The BRAF gene belongs to a class of genes known as oncogenes. When mutated, oncogenes have the potential to cause normal cells to become cancerous.

The BRAF gene gives guidelines to making a protein that transmits specific signals from outside the cell to the cell's nucleus. This protein is a piece of a signaling pathway known as the RAF/MAPK pathway, which controls a few significant cell functions. In particular, the RAF/MAPK pathway directs the development and division (proliferation) of cells, the procedure by which cells develop to specific functions (differentiation), cell movement (migration), and the implosion of cells (apoptosis).

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed BRAF Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total BRAF Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for BRAF Tests market.
• Competitive dynamics insights and trends provided for BRAF Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Roche Diagnostics International Ltd, bioMerieux SA, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, Takara Bio Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, Biocartis Group NV, BGI Genomics Co Ltd, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the BRAF Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving BRAF Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BRAF Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific BRAF Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.